Early discharge after high-dose melphalan and peripheral blood stem cell reinfusion in patients with hematological and non-hematological disease

Leukemia and Lymphoma

Volumn 50, Issue 1, 2009, Pages 80-84

  Anastasia, Antonella ^a   Giglio, Fabio ^a   Mazza, Rita ^a   Sarina, Barbara ^a   Todisco, Elisabetta ^a   Bramanti, Stefania ^a   Castagna, Luca ^a  

^a HUMANITAS CLINICAL AND RESEARCH CENTER   (Italy)

Author keywords

Early discharge; High dose chemotherapy; Melphalan 200; Mixed inpatient outpatient management

Indexed keywords

AMIKACIN; ANTIFUNGAL AGENT; CEFTAZIDIME; GRANULOCYTE COLONY STIMULATING FACTOR; MELPHALAN; PIPERACILLIN PLUS TAZOBACTAM;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER REGRESSION; CONTROLLED STUDY; COST CONTROL; DIARRHEA; DISEASE DURATION; DRUG MEGADOSE; FEBRILE NEUTROPENIA; FEMALE; HEMATOLOGIC DISEASE; HEMATOLOGIC MALIGNANCY; HODGKIN DISEASE; HOSPITAL DISCHARGE; HOSPITAL READMISSION; HUMAN; INFECTION; LENGTH OF STAY; MAJOR CLINICAL STUDY; MALE; MORTALITY; MUCOSA INFLAMMATION; MULTIPLE MYELOMA; MYCOSIS; NAUSEA; NEUTROPHIL COUNT; NONHODGKIN LYMPHOMA; OUTPATIENT CARE; PATIENT CARE; PATIENT SAFETY; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PYREXIA IDIOPATHICA; THROMBOCYTE COUNT; TREATMENT DURATION; TREATMENT OUTCOME; TUMOR ENGRAFTMENT; VOMITING;

ADOLESCENT; ADULT; AGED; FEMALE; HEMATOLOGIC DISEASES; HUMANS; INFUSIONS, PARENTERAL; MALE; MELPHALAN; MIDDLE AGED; NEOPLASMS; PATIENT DISCHARGE; PERIPHERAL BLOOD STEM CELL TRANSPLANTATION; TIME FACTORS;

EID: 59249095482     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190802535098     Document Type: Article

References (25)

1. Gratwohl, A., Baldomero, H., Labar, B., Apperley, J., Urbano-Ispizua, A. and Accreditation Committee of the European Group for Blood and Marrow Transplantation (EBMT) (2004) Evolution of haematopoietic stem cell transplantation in Eastern and Western Europe from 1990 to 2003. A report from the EBMT activity survey. Croat Med J, 45, pp. 689-694.
2. Bodey, G. P., Hart, J. and Freireich, E. J. (1968) Studies of a patient isolation unit and prophylactic antibiotics in cancer chemotherapy. Cancer, 22, pp. 1018-1026.
3. Jantunen, E., Kuittinen, T., Penttila, K., Lehtonen, P., Mahlamaki, E. and Nousiainen, T. (2006) High-dose melphalan supported by autologous stem cell transplantation is safe and feasible in elderly myeloma patients: Comparison with younger patients treated on the same protocol. Bone Marrow Transplant, 37, pp. 917-922.
4. Moreau, P., Facon, T., Leleu, X., Morineau, N., Huyghe, P. Harousseau, J. L. et al. (2002) Comparison of 200 mg/mq melphalan and 8 Gy total body irradiation plus 140 mg/mq melphalan as conditioning regimen for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: Final analysis of the intergroup11 Francophone du Myelome 9502 randomized trial. Blood, 99, pp. 731-735.
5. Magagnoli, M., Castagna, L., Bramanti, S., Balzarotti, M. and Santoro, A. (2004) Single-agent high-dose melphalan followed by peripheral stem cell (PBSC) in lymphoma patients: An effective and well-tolerated conditioning regimen. Bone Marrow Transplant, 33, pp. 1067-1068.
6. Stewart, D. A., Guo, D., Sutherland, J. A., Ruether, B. A., Jones, A. R. Poon, M. C. et al. (1997) Single-agent high-dose melphalan salvage therapy for Hodgkin's disease: Cost, safety, and long-term efficacy. Ann Oncol, 8, pp. 1277-1279.
7. Russell, J. A., Selby, P. J., Ruether, B. A., Mbidde, E. K., Ashley, S. Zulian, G. et al. (1989) Treatment of advanced Hodgkin's disease with high dose melphalan and autologous bone marrow transplantation. Bone Marrow Transplant, 4, pp. 425-429.
8. Selby, P. J., Mbidde, E. K. and Maitland, J. (1986) High-dose melphalan and autologous bone marrow transplant as treatment for refractory Hodgkin's disease. J Clin Oncol, 4, p. 612.
9. Samuels, B. L. and Bitran, J. D. (1995) High-dose intravenous melphalan: a review. J Clin Oncol, 13, pp. 1786-1799.
10. Morabito, F., Martino, M., Stelitano, C., Oliva, E., Kropp, M. Irrera, G. et al. (2002) Feasibility of a mixed inpatient outpatient model of peripheral blood stem cell transplantation for multiple myeloma. Haematologica, 87, pp. 1192-1199.
11. Fernandez-Aviles, F., Carreras, E., Urbano-Ispizua, A., Rovira, M., Martinez, C. Gaya, A. et al. (2006) Case-control comparison of at-home to total hospital care for autologous stem-cell transplantation for hematologic malignancies. J Clin Oncol, 24, pp. 4855-4861.
12. van Tiel, F. H., Harbers, M. M., Kessels, A. G. and Schouten, H. C. (2005) Home care versus hospital care of patients and chemotherapy-induced cytopenia. Ann Oncol, 16, pp. 195-205.
13. Kern, W. V. (2005) Outpatient management in patients with neutropenia after intensive chemotherapy-is it safe?. Ann Oncol, 16, pp. 179-180.
14. Westermann, A. M., Holtkamp, M. M., Linthorst, G. A., van Leeuwen, L., Willemse, E. J. van Dijk, W. C. et al. (1999) At home management of aplastic phase following high-dose chemotherapy with stem cell rescue for hematological and non-hematological malignancies. Ann Oncol, 10, pp. 511-517.
15. Kessinger, A. and Armitage, J. O. (1991) The evolving role: The evolving role of autologousperipheral stem cell transplantion following high- dose therapy for malignancies. Blood, 77, pp. 211-213.
16. Gluck, S., des Rochers, C, Cano, C., Dorreen, M., Germond, C. Gill, K. et al. (1997) High dose chemotherapy followed by autologous blood cell transplantation: A safe and effective approach. Bone Marrow Transplant, 20, pp. 431-434.
17. Herrmann, R. P., Trent, M., Cooney, J. and Carmel, P. K. (1999) Infections in patients managed at home during autologous stem cell transplantation for lymphoma and multiple myeloma. Bone Marrow Transplant, 24, pp. 1213-1217.
18. Ferrara, F., Viola, A., Copia, C., Schiavone, E. M., Celentano, M. Pollio, F. et al. (2004) Outpatient-based peripheral blood stem cell transplatation for patients with multiple myeloma. Hematol J, 5, pp. 222-226.
19. Jagannath, S., Vesole, D. H., Zhang, M., Desikan, K. R., Copeland, N. Jagannath, M. et al. (1997) Feasibility and cost-effectiveness of outpatient autotransplants in multiple myeloma. Bone Marrow Transplant, 20, pp. 445-450.
20. Summers, N., Dawe, U. and Stewart, D. A. (2000) A comparison of inpatient and outpatient ASCT. Bone Marrow Transplant, 26, pp. 389-395.
21. Kassar, M., Medoff, E. and Seropian, S. (2007) Outpatient high-dose melphalan in multiple myeloma patients. Transfus Pract, 47, pp. 115-119.
22. Meisenberg, B. R., Ferran, K., Hollenbach, K., Brehm, T., Jollon, J. and Piro, L. D. (1998) Reduced charges and costs associated with outpatient autologous stem cell transplantation. Bone Marrow Transplant, 21, pp. 927-932.
23. Todisco, E., Castagna, L., Sarina, B., Mazza, R., Magagnoli, M. Balzarotti, M. et al. (2007) CD34+ dose-driven administration of granulocyte colony-stimulating factor after high-dose chemotherapy in lymphoma patients. Eur J Hematol, 78, pp. 111-116.
24. Rizzo, J. D., Vogelsang, G. B., Krumm, S., Frink, B., Mock, V. and Bass, E. B. (1999) Outpatient-based bone marrow transplantation for hamatologic malignancies: Cost saving or cost shifting?. J Clin Oncol, 17, pp. 2811-2818.
25. Barosi, G., Marchetti, M., Alessandrino, P., Locatelli, F., Casula, S. Lunghi, M. et al. (1999) A model for analyzing the cost of autologous peripheral blood progenitor cell (PBPC) transplantation. Bone Marrow Transplant, 23, pp. 719-725.